<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>GLP-1 receptor agonists &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/glp-1-receptor-agonists/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 05 Jan 2026 09:34:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>GLP-1 receptor agonists &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Incretin Modulation Revolutionizes Diabetes, Heart, and Kidney Health</title>
		<link>https://bioengineer.org/incretin-modulation-revolutionizes-diabetes-heart-and-kidney-health/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 05 Jan 2026 09:33:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiovascular health in diabetes]]></category>
		<category><![CDATA[Diabetes Management]]></category>
		<category><![CDATA[diyabet tedavisi]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[GLP-1 reseptör agonistleri** **Açıklama:** 1. **incretin modülasyonu:** Makalenin temel konusu ve anahtar mekanizması. 2. **diyabet tedavisi]]></category>
		<category><![CDATA[incretin therapy]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **incretin modülasyonu]]></category>
		<category><![CDATA[kardiyovasküler sonuçlar]]></category>
		<category><![CDATA[renal outcomes]]></category>
		<category><![CDATA[renal sonuçlar]]></category>
		<guid isPermaLink="false">https://bioengineer.org/incretin-modulation-revolutionizes-diabetes-heart-and-kidney-health/</guid>

					<description><![CDATA[Recent advancements in diabetes therapy have taken a significant turn as researchers delve into incretin modulation, revealing its profound potential to alter cardiovascular and renal outcomes. In a groundbreaking study led by Miramontes-González and colleagues, the focus on incretin-based therapies highlights how they are poised to reshape the landscape of diabetes management, ensuring not only [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">313677</post-id>	</item>
		<item>
		<title>Study Finds GLP-1 Medications Significantly Reduce Mortality in Colon Cancer Patients</title>
		<link>https://bioengineer.org/study-finds-glp-1-medications-significantly-reduce-mortality-in-colon-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 11 Nov 2025 13:29:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer survival benefits]]></category>
		<category><![CDATA[colon cancer mortality]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<guid isPermaLink="false">https://bioengineer.org/study-finds-glp-1-medications-significantly-reduce-mortality-in-colon-cancer-patients/</guid>

					<description><![CDATA[A groundbreaking study conducted by researchers at the University of California San Diego has unveiled compelling evidence suggesting that glucagon-like peptide-1 (GLP-1) receptor agonists—widely recognized for their roles in managing blood glucose and facilitating weight loss—may possess potent survival benefits for patients diagnosed with colon cancer. This novel research, which harnessed real-world data from over [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">294766</post-id>	</item>
		<item>
		<title>How Drunk Do You Feel? Virginia Tech Researchers Find Ozempic, Wegovy May Help Reduce Alcohol Consumption</title>
		<link>https://bioengineer.org/how-drunk-do-you-feel-virginia-tech-researchers-find-ozempic-wegovy-may-help-reduce-alcohol-consumption/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 15 Oct 2025 09:31:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[alcohol use disorder]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[metabolic disorder treatments]]></category>
		<category><![CDATA[pharmacological alcohol modulation]]></category>
		<category><![CDATA[Virginia Tech research]]></category>
		<guid isPermaLink="false">https://bioengineer.org/how-drunk-do-you-feel-virginia-tech-researchers-find-ozempic-wegovy-may-help-reduce-alcohol-consumption/</guid>

					<description><![CDATA[A pioneering study from the Fralin Biomedical Research Institute at Virginia Tech Carilion (VTC) sheds new light on the potential interplay between medications commonly prescribed for diabetes and obesity and alcohol metabolism in the human body. These medications, known as GLP-1 receptor agonists—including semaglutide, tirzepatide, and liraglutide, widely marketed under brands such as Ozempic and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">281236</post-id>	</item>
		<item>
		<title>GLP-1 Receptor Agonists Proven Safe and Effective for Treating Obesity in Adults with Mental Illness</title>
		<link>https://bioengineer.org/glp-1-receptor-agonists-proven-safe-and-effective-for-treating-obesity-in-adults-with-mental-illness/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 10 May 2025 23:23:54 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[GLP-1 safety and efficacy]]></category>
		<category><![CDATA[mental health outcomes]]></category>
		<category><![CDATA[obesity treatment in mental illness]]></category>
		<category><![CDATA[psychotropic-induced metabolic disorders]]></category>
		<guid isPermaLink="false">https://bioengineer.org/glp-1-receptor-agonists-proven-safe-and-effective-for-treating-obesity-in-adults-with-mental-illness/</guid>

					<description><![CDATA[In a groundbreaking synthesis of current clinical evidence, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for diabetes management, are emerging as potent agents in combating metabolic disturbances commonly observed in individuals with severe mental illness. This revelation, unveiled at the European Congress on Obesity in Malaga, heralds a promising frontier in addressing the pervasive [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">244449</post-id>	</item>
		<item>
		<title>No link found between popular diabetes medication and suicide</title>
		<link>https://bioengineer.org/no-link-found-between-popular-diabetes-medication-and-suicide/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 03 Sep 2024 15:20:24 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[diabetes medication]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[Mental Health]]></category>
		<category><![CDATA[Observational study]]></category>
		<category><![CDATA[suicide risk]]></category>
		<guid isPermaLink="false">https://bioengineer.org/no-link-found-between-popular-diabetes-medication-and-suicide/</guid>

					<description><![CDATA[There has been concern that common diabetes drugs could increase the risk of suicide and self-harm. In a new study, led by researchers at Karolinska Institutet and published in Jama Internal Medicine, no such risk increase was observed. There has been concern that common diabetes drugs could increase the risk of suicide and self-harm. In [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">232515</post-id>	</item>
	</channel>
</rss>
